SUMMARY Migraine occurs with increased frequency in patients with systemic lupus erythematosus and in subjects suffering from Raynaud's phenomenon without any underlying connective tissue disorders. A possible link between migraine and Raynaud's phenomenon has been suggested. Two rheumatic conditions where Raynaud's phenomenon occurs very commonly are scleroderma and primary Sjogren's syndrome. It is possible that migraine is also common in these disorders but has been unrecognised. Therefore, the prevalence of migraine was assessed by a questionnaire in 191 subjects suffering from various connective tissue disorders and control subjects. Migraine was diagnosed in 16/35 (46%) patients with primary Sjogren's syndrome, 31/97 (32%) patients with scleroderma, 4/33 (12%) patients with rheumatoid arthritis/Sjogren's syndrome compared with 3/26 (11%) control subjects. A family history of headaches was more common in the patient groups than controls. There was a significant association between occurrence of Raynaud's phenomenon and migraine. Small vessel pathology may underlie both migraine and Raynaud's phenomenon in these connective tissue disorders-as has been suggested in systemic lupus erythematosus. The findings stress the need to ask specifically about complaints of headaches/migraines in patients with scleroderma and primary Sjogren's syndrome for the appropriate total management of these patients.
According to this scoring system a diagnosis of Raynaud's phenomenon was made if the total score was four or more.
Patients were also questioned about the timing of the episodes of the Raynaud's phenomenon and headaches, if any, and whether there was any temporal relation between the two. The results were analysed by x2 test.
Results
Migraine was diagnosed according to criteria described above. Patients with headache but without any migrainous accompaniment were considered to have non-migrainous headaches.
Headaches were complained of by 26 patients (74%) in the group with primary SS, 11 patients (33%) in the RA/SS group, 43 patients (44%) in the scleroderma group, and 13 patients (50%) in the normal control group (Table 1) . Prevalence of headaches in the group with primary SS only was significantly different from that of the control group (p=O0O5).
On further analysis of patients who admitted to headaches, characteristics for migraine were fulfilled by the patients as follows: 16 (46%) in the primary SS group, 4 (12%) in the RA/SS group, 31 (32%) in the scleroderma group, and 3 (11%) in the control group (Table 1) . Migraine was significantly more common in both primary SS (p=0-01) and scleroderma (p=005) than in the control group.
A past history of migraine was found in three patients in the scleroderma group and in one patient in each of the other three groups (Table 1) . Table 1 shows the frequencies with which migraine episodes occurred in the different categories of SS and other patients. It can be seen that patients in the primary SS and scleroderma groups, in particular, had more frequent migraine attacks than those in the other two groups. Table 1 also shows the severity of the migraine in the different categories of patients. Again it is apparent that the more severe episodes of migraine occurred mainly in the primary SS and scleroderma groups.
A number of patients in each category did not answer the question about a family history of headaches, but a positive family history was found more frequently in the primary SS and scleroderma groups than in the RA/SS group and the normal subjects. Raynaud's phenomenon by the criteria detailed above was found, as expected, in most patients in the scleroderma group, where 86 patients (89%) had relevant symptoms. A surprisingly high proportion of patients in the primary SS group (18 patients; 51%) also admitted to Raynaud's phenomenon, while 10 patients (30%) in the RA/SS group and four normal subjects (15%) admitted to symptoms characteristic of Raynaud's phenomenon (Table 2) .
Two patients in the group with primary SS and five in the scleroderma group admitted to an association between Raynaud's phenomenon and migraine, while none in the RA/SS group or normal control group noticed any such relation (Table 2) . Table 3 gives the occurrence of migraine in patients with Raynaud's phenomenon. Statistical analysis showed that there was a significant association between the occurrence of Raynaud's phenomenon and migraine. An analysis of the drugs taken by the patients showed that most patients, particularly in the RA/SS and the primary SS groups, were taking analgesics or non-steroidal anti-inflammatory drugs, or both. It is noteworthy that blockers were not being taken by any of the patients, and a significant proportion of the patients with scleroderma (21%) were taking vasodilators such as nifedipine, ketanserin, or others. Other vasodilators as well as specific antimigraine drugs had been prescribed only for the group of patients with scieroderma but not for the other groups. Oral contraceptive drugs were being taken by three patients in the scleroderma group but by none in the other groups.
Discussion
This study shows a significantly higher prevalence of migraine in patients with primary SS and scleroderma, than in the RA/SS and normal control groups. Migraine had not been sought specifically in these patient categories in the past. It may be that in the presence of other disabling symptoms and dramatic clinical manifestations, which may occur in patients with scleroderma in particular, complaints of headaches in these patients have been ignored or overlooked. In SLE claims that migraine occurs frequentlyi) l have been confirmed by Isenberg et al by a questionnaire survey designed to pick out complaints of migraine.' The relatively high prevalence of migraine in the normal population as well as in patients with SLE suggested the need for a controlled study in patients with primary SS and scleroderma to determine the significance of these previous observations. In the general population'2 and in a previous survey a prevalence of 5% was found in the rheumatology outpatient population.'3 The latter study, however, was uncontrolled.
It is noteworthy from the present survey that 50% of the control subjects and a third of the patients with RA/SS admitted to headaches, thus reflecting the common prevalence of non-specific headaches in the general population as referred to above. Only three (11%) of the normal control group admitted to migraine, however, compared with the much higher prevalences in the patients with primary SS and scleroderma.
Raynaud's phenomenon was found, as expected in most patients with scleroderma but, surprisingly, also in over half the patients in the primary SS group. There was no significant association between the attacks of Raynaud's phenomenon and migraine, though it is noteworthy that over 5% of the patients in the primary SS and scleroderma groups admitted to a temporal relation, while none of the other two groups did so. It has been suggested that small vessel Headaches and migraine in Sjogren's syndrome 315 disease may reflect the clinical manifestations of SLE, including Raynaud's phenomenon, and may contribute to cerebrovascular dysfunction causing migraines.'4 A similar mechanism may underlie the migraine in the patient groups studied in this survey-that is, primary SS and scleroderma groups, and needs to be studied.
The association of migraine with connective tissue disorders such as SLE, scleroderma, and primary SS may indicate a link between these disorders, for which there may be common pathogenetic mechanisms, and further work on this may shed some light on the aetiopathogenesis of these diseases. In support of such a link, in SLE at least, is the fact that migrainous phenomena have been noted to be commonly associated with disease exacerbation and to subside with a decrease in disease activity. 13 Further support for this concept comes from the observations of these authors that corticosteroids were more effective in controlling the vascular headache and scotomata of some of their patients with SLE than were analgesics and conventional antimigraine treatment.
The headache phase of migraine is thought to arise as a result of dilatation and sterile inflammation around branches of the external carotid artery. 14 Research has focused on the part played by vasoactive substances, such as serotonin and others-for example, bradykinin and prostaglandins,i5 in the observed vascular responses of the intracranial and extracranial circulation in this condition. Similar phenomena may underlie vascular headaches in scleroderma and primary SS as has been suggested in patients with SLE.'3 There may be a primary neurological basis for migraine, however, and the vascular phenomena may be secondary to neurological changes as argued by Blau. '6 Because of the reported high prevalence of migraine in subjects with Raynaud's phenomenon3 in a non-rheumatic population we analysed the results to explore the possibility that such an association may exist in rheumatic patients with high prevalence of Raynaud's phenomenon as studied in this series. This study showed that such an association does exist in primary SS and scleroderma.
It is interesting to note that more family members of patients with primary SS and scleroderma suffered from headaches than family members of the other two groups, but it was not possible to ascertain from the questionnaire what proportion of these family members actually suffered from migraine.
A few remarks are necessary about the drugs taken by the patients in this survey. It is particularly noteworthy that , blockers were conspicuously absent from the drug list in the patient groups; there was also no association between oral contraceptives and prevalence of migraine in either the patients with primary SS or scleroderma.
It might be argued that the increased prevalence of migraine found in the patients with primary SS and scleroderma in this survey is a non-specific result of the stress and emotional upheavals associated with the disease. The possibility remains, however, that migraine in primary SS and scleroderma may in part be due to the underlying disease process as in the case of SLE. In view of the findings of this study patients with primary SS and scleroderma should be asked specifically about headaches and, in particular, migrainous headaches as they may be additional disabilities for these patients. The reward of such specific inquiries lies in the availability of specific antimigrainous treatment, which these patients might otherwise be denied.
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